The agency said providers should consider retesting positive patient specimens from either of the two tests (Alinity m SARS-CoV-2 AMP kit, list number 09N78-095, and Alinity m Resp-4-Plex AMP kit, list number 09N79-096) performed in the last two weeks with a different authorized test. The agency also said providers should consider informing patients with positive results since June that their results may have been erroneous.
In an email statement, Abbott said it is “implementing an update to its Alinity m SARS-CoV-2 EUA assay. The update to the SARS-CoV-2 EUA assay is nearly complete. We are also updating our Resp-4-plex EUA assay, which will be completed in next two weeks (in the U.S.).”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
